Is TECPR2 p.Gly536Ser (c.1606G>A) pathogenic?

TECPR2 p.Gly536Ser (c.1606G>A) is classified Uncertain significance in TECPR2 (ClinVar, Multiple submitters, 6 submitters; last evaluated 2025-09-05). AlphaMissense: likely benign (0.0778); Ultra-rare (popmax 0.0176%, mid); Associated with Inborn genetic diseases.

What condition is associated with TECPR2 p.Gly536Ser (c.1606G>A)?

TECPR2 p.Gly536Ser (c.1606G>A) is associated with Inborn genetic diseases, hereditary spastic paraplegia 49, hereditary spastic paraplegia (ClinVar).

How common is TECPR2 p.Gly536Ser (c.1606G>A) in the general population?

TECPR2 p.Gly536Ser (c.1606G>A) is ultra-rare (popmax 0.0176%, mid) (gnomAD).

What do computational predictors say about TECPR2 p.Gly536Ser (c.1606G>A)?

AlphaMissense predicts likely benign (score 0.0778) — an in-silico prediction, not a clinical call.

TECPR2 p.Gly536Ser

c.1606G>A · rs186595127 · VCV473089

Uncertain significance Multiple submitters

Classification

Uncertain significance

ClinVar

Review

Multiple submitters ★★☆☆

ClinVar · 6 submitters

AlphaMissense

likely benign

0.0778 · ACMG-weighted

gnomAD v4.1

Rare

ultra-rare (popmax 0.0176%, mid)

Missense predictors

0/3 damaging

AlphaMissense, REVEL, SaProt

Conditions

Inborn genetic diseases

Computational evidence

Protein change
AlphaMissense	0.0778	likely benign
REVEL	0.022	moderately benign-leaning
SaProt	LLR -6.55	tolerated
⇒ AlphaMissense, REVEL and SaProt all call this tolerated.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 0.5	GERP -3, phastCons 0.002
Regional constraint	o/e 0.85	unconstrained · MANE · 122 kb · p 2.1e-10 · regional, not allelic
Overall
CADD	5.822	PHRED · no single calibrated threshold — expert panels disagree

ClinVar classifies this uncertain; the computational predictors unanimously lean tolerated — a triage signal, not a reclassification

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.0176% Middle Eastern · 1/5,688 alleles

Filtering AF 0.0105% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.00989%

Overall 0.00974% 149/1,530,506 alleles · ultra-rare exomes 130/1,378,362 · genomes 19/152,144 · joint denominator

Ancestry group	Frequency	1 in
Middle Easterngrpmax	0.0176%	5,688
European (non-Finnish)	0.0122%	8,207
Finnishnot grpmax-eligible	0.00493%	20,287
Admixed American	0.00432%	23,129
Remaining individualsnot grpmax-eligible	0.0034%	29,377
African / African-American	0.00139%	72,110
South Asian	0.0013%	77,052

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: TECPR2
Protein: p.Gly536Ser
Coding: c.1606G>A
MANE Select: NM_014844
dbSNP: rs186595127
Type: single nucleotide variant
Location: chr14:102434423 (GRCh38)
Gene constraint: LOEUF 0.607 · pLI <0.01 · ClinGen HI gene assoc. with recessive phenotype (gnomAD)
Structure: AlphaFold pLDDT 68.27
Residue 536: the 'disordered' region

Full TECPR2 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

Inborn genetic diseases — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: hereditary spastic paraplegia 49 hereditary spastic paraplegia

Similar variants

TECPR2 p.Gly536Arg Conflicting classifications of pathogenicity ★ ⚠ same residue
TECPR2 p.Gly536Cys Uncertain significance ★ ⚠ same residue
TECPR2 p.Gly536= Likely benign ★ same residue
TECPR2 c.1084+2T>C Likely pathogenic ★★ same condition
TECPR2 c.1418-2A>G Likely pathogenic ★★ same condition
TECPR2 c.2753-1G>A Likely pathogenic ★★ same condition
TECPR2 p.Gln1189Ter Pathogenic/Likely pathogenic ★★ same condition
TECPR2 p.Gln191Ter Pathogenic/Likely pathogenic ★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/tecpr2-p-gly536ser (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown